222 related articles for article (PubMed ID: 37628729)
1. Cell-Impermeable Inhibitors Confirm That Intracellular Human Transglutaminase 2 Is Responsible for the Transglutaminase-Associated Cancer Phenotype.
Gates EWJ; Calvert ND; Cundy NJ; Brugnoli F; Navals P; Kirby A; Bianchi N; Adhikary G; Shuhendler AJ; Eckert RL; Keillor JW
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628729
[TBL] [Abstract][Full Text] [Related]
2. High-Affinity Fluorogenic Substrate for Tissue Transglutaminase Reveals Enzymatic Hysteresis.
Gates EWJ; Prince-Hallée A; Heidari Y; Sedighi A; Keillor JW
Biochemistry; 2023 Nov; 62(21):3085-3095. PubMed ID: 37856791
[TBL] [Abstract][Full Text] [Related]
3. Discovery and Characterization of PROTACs Targeting Tissue Transglutaminase (TG2).
Valdivia A; Vagadia PP; Guo G; O'Brien E; Matei D; Schiltz GE
J Med Chem; 2023 Jul; 66(14):9445-9465. PubMed ID: 37449845
[TBL] [Abstract][Full Text] [Related]
4. Role of Transglutaminase 2 in Cell Death, Survival, and Fibrosis.
Tatsukawa H; Hitomi K
Cells; 2021 Jul; 10(7):. PubMed ID: 34360011
[TBL] [Abstract][Full Text] [Related]
5. Transglutaminase 2 interactions with extracellular matrix proteins as probed with celiac disease autoantibodies.
Cardoso I; Stamnaes J; Andersen JT; Melino G; Iversen R; Sollid LM
FEBS J; 2015 Jun; 282(11):2063-75. PubMed ID: 25808416
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of tissue transglutaminase.
Keillor JW; Apperley KY; Akbar A
Trends Pharmacol Sci; 2015 Jan; 36(1):32-40. PubMed ID: 25500711
[TBL] [Abstract][Full Text] [Related]
7. Sulforaphane covalently interacts with the transglutaminase 2 cancer maintenance protein to alter its structure and suppress its activity.
Rorke EA; Adhikary G; Szmacinski H; Lakowicz JR; Weber DJ; Godoy-Ruiz R; Puranik P; Keillor JW; Gates EWJ; Eckert RL
Mol Carcinog; 2022 Jan; 61(1):19-32. PubMed ID: 34610184
[TBL] [Abstract][Full Text] [Related]
8. Immuno-Sensing at Ultra-Low Concentration of TG2 Protein by Organic Electrochemical Transistors.
Preziosi V; Barra M; Villella VR; Esposito S; D'Angelo P; Marasso SL; Cocuzza M; Cassinese A; Guido S
Biosensors (Basel); 2023 Mar; 13(4):. PubMed ID: 37185523
[TBL] [Abstract][Full Text] [Related]
9. Transglutaminase 2: Development of therapeutic antibodies reveals four inhibitory epitopes and confirms extracellular function in fibrotic remodelling.
Maamra M; Benayad OM; Matthews D; Kettleborough C; Atkinson J; Cain K; Bon H; Brand H; Parkinson M; Watson PF; Johnson TS
Br J Pharmacol; 2022 Jun; 179(11):2697-2712. PubMed ID: 34879432
[TBL] [Abstract][Full Text] [Related]
10. Tissue transglutaminase: a multifunctional and multisite regulator in health and disease.
Yao Z; Fan Y; Lin L; Kellems RE; Xia Y
Physiol Rev; 2024 Jan; 104(1):281-325. PubMed ID: 37712623
[TBL] [Abstract][Full Text] [Related]
11. Biological Implications and Functional Significance of Transglutaminase Type 2 in Nervous System Tumors.
Buccarelli M; Castellani G; Fiorentino V; Pizzimenti C; Beninati S; Ricci-Vitiani L; Scattoni ML; Mischiati C; Facchiano F; Tabolacci C
Cells; 2024 Apr; 13(8):. PubMed ID: 38667282
[TBL] [Abstract][Full Text] [Related]
12. Conformational Modulation of Tissue Transglutaminase via Active Site Thiol Alkylating Agents: Size Does Not Matter.
Navals P; Rangaswamy AMM; Kasyanchyk P; Berezovski MV; Keillor JW
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672511
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the development of tissue transglutaminase (TG2) inhibitors.
Badarau E; Collighan RJ; Griffin M
Amino Acids; 2013 Jan; 44(1):119-27. PubMed ID: 22160259
[TBL] [Abstract][Full Text] [Related]
14. The Role of Transglutaminase 2 in Cancer: An Update.
Zaltron E; Vianello F; Ruzza A; Palazzo A; Brillo V; Celotti I; Scavezzon M; Rossin F; Leanza L; Severin F
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474044
[TBL] [Abstract][Full Text] [Related]
15. Sulfated glycosaminoglycans inhibit transglutaminase 2 by stabilizing its closed conformation.
Müller CD; Ruiz-Gómez G; Cazzonelli S; Möller S; Wodtke R; Löser R; Freyse J; Dürig JN; Rademann J; Hempel U; Pisabarro MT; Vogel S
Sci Rep; 2022 Aug; 12(1):13326. PubMed ID: 35922533
[TBL] [Abstract][Full Text] [Related]
16. The complex role of transglutaminase 2 in glioblastoma proliferation.
Gundemir S; Monteagudo A; Akbar A; Keillor JW; Johnson GVW
Neuro Oncol; 2017 Feb; 19(2):208-218. PubMed ID: 27591334
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships of N-terminal variants of peptidomimetic tissue transglutaminase inhibitors.
McNeil NMR; Gates EWJ; Firoozi N; Cundy NJ; Leccese J; Eisinga S; Tyndall JDA; Adhikary G; Eckert RL; Keillor JW
Eur J Med Chem; 2022 Mar; 232():114172. PubMed ID: 35158154
[TBL] [Abstract][Full Text] [Related]
18. The Outside-In Journey of Tissue Transglutaminase in Cancer.
Sima LE; Matei D; Condello S
Cells; 2022 May; 11(11):. PubMed ID: 35681474
[TBL] [Abstract][Full Text] [Related]
19. Implications of enigmatic transglutaminase 2 (TG2) in cardiac diseases and therapeutic developments.
Al-U'datt DGF; Tranchant CC; Al-Dwairi A; Alqudah M; Al-Shboul O; Hiram R; Allen BG; Jaradat S; Alqbelat J; Abu-Zaiton AS
Biochem Pharmacol; 2022 Jul; 201():115104. PubMed ID: 35617996
[TBL] [Abstract][Full Text] [Related]
20. Biological functionalities of transglutaminase 2 and the possibility of its compensation by other members of the transglutaminase family.
Odii BO; Coussons P
ScientificWorldJournal; 2014; 2014():714561. PubMed ID: 24778599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
